{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:03:00Z","timestamp":1791669780686,"version":"4.3.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministre de l\u2019\u00c9conomie et Innovation"},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche Sant\u00e9 Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MUHC Foundation"},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Omalizumab is an anti-immunoglobulin E monoclonal antibody used to treat moderate to severe chronic idiopathic urticaria, asthma, and nasal polyps. Recent research suggested that omalizumab may enhance the innate antiviral response and have anti-inflammatory properties.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We aimed to investigate the efficacy and safety of omalizumab in adults hospitalized for coronavirus disease 2019 (COVID-19) pneumonia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a phase II randomized, double blind, placebo-controlled trial comparing omalizumab with placebo (in addition to standard of care) in hospitalized patients with COVID-19. The primary endpoint was the composite of mechanical ventilation and\/or death at day 14. Secondary endpoints included all-cause mortality at day 28, time to clinical improvement, and duration of hospitalization.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 41 patients recruited, 40 were randomized (20 received the study drug and 20 placebo). The median age of the patients was 74 years and 55.0% were male. Omalizumab was associated with a 92.6% posterior probability of a reduction in mechanical ventilation and death on day 14 with an adjusted odds ratio of 0.11 (95% credible interval 0.002-2.05). Omalizumab was also associated with a 75.9% posterior probability of reduced all-cause mortality on day 28 with an adjusted odds ratio of 0.49 (95% credible interval, 0.06-3.90). No statistically significant differences were found for the time to clinical improvement and duration of hospitalization. Numerically fewer adverse events were reported in the omalizumab group and there were no drug-related serious adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results suggest that omalizumab could prove protective against death and mechanical ventilation in hospitalized patients with COVID-19. This study could also support the development of a phase III trial program investigating the antiviral and anti-inflammatory effect of omalizumab for severe respiratory viral illnesses requiring hospital admission.<\/jats:p>\n                  <jats:p>ClinicalTrials.gov ID: NCT04720612<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae102","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T23:00:25Z","timestamp":1708729225000},"source":"Crossref","is-referenced-by-count":3,"title":["COVID-19 Immunologic Antiviral Therapy With Omalizumab (CIAO)\u2014a Randomized Controlled Clinical Trial"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9393-0922","authenticated-orcid":false,"given":"Michelle","family":"Le","sequence":"first","affiliation":[{"name":"Division of Dermatology, Department of Medicine, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Khoury","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6790-220X","authenticated-orcid":false,"given":"Connor","family":"Prosty","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Cormier","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Medicine, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4867-2063","authenticated-orcid":false,"given":"Mathew P","family":"Cheng","sequence":"additional","affiliation":[{"name":"Divisions of Infectious Diseases & Medical Microbiology, McGill University , McGill's Interdisciplinary Initiative in Infection and Immunity, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fowler","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Sunnybrook Health Sciences Centre , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9476-839X","authenticated-orcid":false,"given":"Srinivas","family":"Murthy","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Faculty of Medicine, University of British Columbia , Vancouver, BC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L Y","family":"Tsang","sequence":"additional","affiliation":[{"name":"Niagara Health Knowledge Institute, Niagara Health, St. Catharines, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Ben-Shoshan","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Dermatology, Department of Pediatrics, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Rahme","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirin","family":"Golchi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini","family":"Dendukuri","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics, and Occupational Health, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2267-4239","authenticated-orcid":false,"given":"Todd C","family":"Lee","sequence":"additional","affiliation":[{"name":"Divisions of Infectious Diseases & Medical Microbiology, McGill University , McGill's Interdisciplinary Initiative in Infection and Immunity, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6692-7787","authenticated-orcid":false,"given":"Elena","family":"Netchiporouk","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, McGill University , Montreal, QC , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"2024042607412877600_ofae102-B1","volume-title":"Statpearls","author":"Cascella","year":"2022"},{"key":"2024042607412877600_ofae102-B2","doi-asserted-by":"crossref","first-page":"n436","DOI":"10.1136\/bmj.n436","article-title":"Severe COVID-19 pneumonia: pathogenesis and clinical management","volume":"372","author":"Attaway","year":"2021","journal-title":"BMJ"},{"key":"2024042607412877600_ofae102-B3","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"COVID-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"2024042607412877600_ofae102-B4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa2203965","article-title":"Effects of previous infection and vaccination on symptomatic omicron infections","volume":"387","author":"Altarawneh","year":"2022","journal-title":"N Engl J Med"},{"key":"2024042607412877600_ofae102-B5","doi-asserted-by":"crossref","first-page":"100208","DOI":"10.1016\/j.lanepe.2021.100208","article-title":"Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study","volume":"10","author":"Naaber","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"2024042607412877600_ofae102-B6","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"2024042607412877600_ofae102-B7","doi-asserted-by":"publisher","author":"Antonelli","DOI":"10.1101\/2021.05.24.21257738"},{"key":"2024042607412877600_ofae102-B8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41392-021-00849-0","article-title":"SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury","volume":"6","author":"Wu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2024042607412877600_ofae102-B9","doi-asserted-by":"crossref","first-page":"580679","DOI":"10.3389\/fcimb.2021.580679","article-title":"Divergent mast cell responses modulate antiviral immunity during influenza virus infection","volume":"11","author":"Murphy-Schafer","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2024042607412877600_ofae102-B10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3389\/fimmu.2015.00394","article-title":"Mast cells as regulators of T cell responses","volume":"6","author":"Bulfone-Paus","year":"2015","journal-title":"Front Immunol"},{"key":"2024042607412877600_ofae102-B11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.coi.2020.05.003","article-title":"Protective and pathogenic roles for mast cells during viral infections","volume":"66","author":"Rathore","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"2024042607412877600_ofae102-B12","first-page":"e149834","article-title":"Mast cell activation in lungs during SARS-CoV-2 infection associated with lung pathology and severe COVID-19","volume-title":"J Clin Invest","author":"Tan","year":"2023"},{"key":"2024042607412877600_ofae102-B13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41586-020-03118-2","article-title":"Local immune response to food antigens drives meal-induced abdominal pain","volume":"590","author":"Aguilera-Lizarraga","year":"2021","journal-title":"Nature"},{"key":"2024042607412877600_ofae102-B14"},{"key":"2024042607412877600_ofae102-B15","doi-asserted-by":"crossref","first-page":"100741","DOI":"10.1016\/j.waojou.2023.100741","article-title":"Omalizumab may protect allergic patients against COVID-19: a systematic review","volume":"16","author":"Ghiglioni","year":"2023","journal-title":"World Allergy Organ J"},{"key":"2024042607412877600_ofae102-B16","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/ijd.15134","article-title":"Chronic spontaneous urticaria exacerbation in a patient with COVID-19: rapid and excellent response to omalizumab","volume":"59","author":"Criado","year":"2020","journal-title":"Int J Dermatol"},{"key":"2024042607412877600_ofae102-B17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.rmed.2018.06.021","article-title":"Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: a long-term post-marketing study in Japan","volume":"141","author":"Adachi","year":"2018","journal-title":"Respir Med"},{"key":"2024042607412877600_ofae102-B18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5114\/ada.2018.76606","article-title":"Real-world effectiveness and safety of omalizumab in patients with uncontrolled severe allergic asthma from the Czech Republic","volume":"36","author":"Kirchnerov\u00e1","year":"2019","journal-title":"Postepy Dermatol Alergol"},{"key":"2024042607412877600_ofae102-B19","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.rmed.2013.04.017","article-title":"The eXpeRience registry: the \u201creal-world\u201d effectiveness of omalizumab in allergic asthma","volume":"107","author":"Braunstahl","year":"2013","journal-title":"Respir Med"},{"key":"2024042607412877600_ofae102-B20","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.jaci.2017.07.013","article-title":"Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics","volume":"140","author":"Lieberman","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2024042607412877600_ofae102-B21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1208\/s12248-015-9821-x","article-title":"Evaluation of IgE antibodies to omalizumab (Xolair\u00ae) and their potential correlation to anaphylaxis","volume":"18","author":"Baker","year":"2016","journal-title":"AAPS J"},{"key":"2024042607412877600_ofae102-B22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"key":"2024042607412877600_ofae102-B23","doi-asserted-by":"crossref","first-page":"11610","DOI":"10.1038\/ncomms11610","article-title":"Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange","volume":"7","author":"Pennington","year":"2016","journal-title":"Nat Commun"},{"key":"2024042607412877600_ofae102-B24","first-page":"38","article-title":"Longitudinal study of the expression of Fc\u03b5RI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with omalizumab","volume":"47","author":"Pereira Santos","year":"2015","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"2024042607412877600_ofae102-B25","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1081-1206(10)61170-2","article-title":"Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells","volume":"95","author":"Huang","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024042607412877600_ofae102-B26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.bbrc.2017.02.090","article-title":"Preventative effect of OMZ-SPT on lipopolysaccharide-induced acute lung injury and inflammation via nuclear factor-kappa B signaling in mice","volume":"485","author":"Wang","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"2024042607412877600_ofae102-B27","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.jaci.2017.07.035","article-title":"Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab","volume":"141","author":"Gill","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2024042607412877600_ofae102-B28","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaci.2020.01.035","article-title":"Understanding the asthmatic response to an experimental rhinovirus infection: exploring the effects of blocking IgE","volume":"146","author":"Heymann","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2024042607412877600_ofae102-B29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1001\/jama.2021.9941","article-title":"Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances: the CONSERVE 2021 statement","volume":"326","author":"Orkin","year":"2021","journal-title":"JAMA"},{"key":"2024042607412877600_ofae102-B30","author":"Center for Drug Evaluation, Research"},{"key":"2024042607412877600_ofae102-B31","author":"Foundation for Statistical Computing RR"},{"key":"2024042607412877600_ofae102-B32","author":"Plummer"},{"key":"2024042607412877600_ofae102-B33","doi-asserted-by":"crossref","first-page":"e12279","DOI":"10.1002\/clt2.12279","article-title":"Omalizumab prevents respiratory illnesses in non-atopic chronic spontaneous urticaria patients: a prospective, parallel-group, pilot pragmatic trial","volume":"13","author":"Konstantinou","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"2024042607412877600_ofae102-B34","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2024042607412877600_ofae102-B35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201701-0120OC","article-title":"Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma","volume":"196","author":"Esquivel","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024042607412877600_ofae102-B36","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1164\/rccm.201606-1145LE","article-title":"Omalizumab is associated with reduced acute severity of rhinovirus-triggered asthma exacerbation","volume":"194","author":"Kantor","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2024042607412877600_ofae102-B37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ajd.14019","article-title":"Omalizumab treatment in combination with any other biologics: is it really a safe duo?","volume":"64","author":"Ko\u00e7 Y\u0131ld\u0131r\u0131m","year":"2023","journal-title":"Australas J Dermatol"},{"key":"2024042607412877600_ofae102-B38","doi-asserted-by":"crossref","first-page":"AB193","DOI":"10.1016\/j.jaci.2021.12.635","article-title":"Combining biologic therapies involving anti-IgE, anti-IL5, anti-IL5R and anti IL-4\/IL-13: experience from a large academic health system","volume":"149","author":"Pitlick","year":"2022","journal-title":"J Allergy Clin Immunol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae102\/56750034\/ofae102.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/4\/ofae102\/57124576\/ofae102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/4\/ofae102\/57124576\/ofae102.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T07:42:01Z","timestamp":1714117321000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae102\/7613433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae102","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,2,23]]},"article-number":"ofae102"}}